[OPG/RANKL: role and therapeutic target in osteoporosis].
Given the increasing risk of fractures with aging in western countries, there is a need for the development of safe and efficient anti-osteoporotic drugs for the prevention and treatment of osteoporosis. Recent studies have provided evidence for an essential role of RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) and its decoy receptor osteoprotegerin in the control of osteoclast differentiation and survival. Post-menopausal osteoporosis results from an imbalance between resorption and formation associated with decreased OPG/RANKL. Targeting the OPG/RANKL system may therefore have a beneficial impact in osteoporosis. Accordingly, the development of novel strategies targeting OPG/RANKL using anti-RANKL or therapeutic intervention proved to be efficient to reduce bone resorption and to prevent bone loss in postmenopausal osteoporosis. This opens the way for novel therapeutic strategies for correcting bone metabolism in various pathologic disorders characterized by increased bone remodelling and bone loss.
Marie
Pierre
P
Directeur de recherche au CNRS, INSERM U606 et Université Paris 7, Hôpital Lariboisière, 2 rue Ambroise Paré, Paris Cedex 10, France. pierre.marie@larib.Inserm.fr
Halbout
Philippe
P
D016723:Bone Remodeling; D006801:Humans; D008954:Models, Biological; D010006:Osteoblasts / Q000502:physiology; D010024:Osteoporosis / Q000503:physiopathology / Q000628:therapy*; D053245:RANK Ligand / Q000502:physiology*
D053245:RANK Ligand